jCyte
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
23 Corporate Plaza Dr Ste 150, Newport B...Phone Number
(949) 824-0275Website
www.jcyte.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About jCyte
jCyte Inc. is focused on developing innovative therapies for degenerative retinal disorders, particularly retinitis pigmentosa, through its investigational jCell therapy. The company is engaged in multiple drug development programs aimed at preserving and restoring vision in patients with inherited retinal and blinding diseases. jCyte is committed to improving the lives of patients by creating best-in-class treatments for these conditions. They are also actively seeking talented individuals to join their team in this mission.Explore more
jCyte Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is jCyte your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
jCyte, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at jCyte
Website visits: Recent activity has been detected on your website
Check if jCyte has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on jCyte recently announced quarterly report
Product Launch: Get notified when jCyte launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if jCyte is spiking on competitors!
Click to see if jCyte had a recent Job posting/layoffs
Funding: Get notified immidiatlly once jCyte has new funding data
Recommended Actions
Find VP level buyers at jCyte
Find more new buyers
Compare Similar Companies to jCyte
Compare insights from companies similar to jCyte, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
jCyte is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
jCyte is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about jCyte.
jCyte Tech Stack
A closer look at the technologies used by jCyte
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Event
Person-Based
Events, Search, Medical Research
Event
Events
jCyte News & Media
jCyte, Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting and Outlines Plans to Start Pivotal Trial of jCell® for Retinitis Pigmentosa in the Second Half of 2024
NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- #RP--jCyte, Inc., a pioneering biotechnology company dedicated to preserving and restoring vision in patients with retinitis pigmentosa (RP) and other degenerative retinal disorders, is pleased to announce the successful outcome of its pre-phase 3 Type B meeting with the US Food and Drug Administration (FDA) held on January 16, 2024. Additionally, the company is gearing up to commence its pivotal US trial for jCell in the second half of 2024. JohnjCyte Announces Appointment of Dr. Stewart Craig as Chief Technology Officer
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the expansion of the company’s leadership team with the appointment of Dr. Stewart Craig as Chief Technology Officer. In his new role, Dr. Craig will be the strategic and technical lead for all drug product development activities, including manufacturing process development, GMP facility design, build-out and scale-up, tejCyte Identifies Key Anatomical Biomarker Predictive of Substantial Restoration of Visual Function in Retinitis Pigmentosa Patients Treated With jCell Therapy
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--jCyte, Inc., today announced key findings presented at AAO 2021 which demonstrated that retinitis pigmentosa (RP) patients with a baseline central visual field diameter greater than 20 degrees had a profound response to jCell treatment in its Phase 2b study, the largest randomized clinical trial ever conducted in RP for a locally administered investigational treatment. Baruch Kuppermann, MD, PhD, Chairman of the Department of Ophthalmology at the UCI GavijCyte Announces Appointment of Peter C. Kuper as Senior Vice President of Finance and Information Technology
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the company’s leadership team with the appointment of Peter Kuper as Senior Vice President of Finance and Information Technology. Mr. Kuper joins jCyte with over 25 years of investment banking, security analysis, and venture capital experience having played significant leadership roles in making
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding jCyte
Sign Up For FreeTo access detailed company insights
jCyte Inc. is focused on developing innovative therapies for degenerative retinal disorders, particularly retinitis pigmentosa, through its investigational jCell therapy. The company is engaged in multiple drug development programs aimed at preserving and restoring vision in patients with inherited retinal and blinding diseases. jCyte is committed... Read More
